Levetiracetam Tablet, Film Coated
Product Images NDC 0904-7124

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0904-7124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 00)

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 00)
This is a prescription drug with the brand name Levitiracetam. It comes in a package of 100 tablets identified by the NDC codes 0904-7125-61 and 0804-7125. The tablets are unit-dosed at 750 mg strength. It may only be dispensed by a licensed pharmacist with a medication guide. The product insert contains complete dosage recommendations, prescribing information, cautions, and warnings. This drug needs to be stored at 20-25°C (68-77°F), and the package is not designed to be child-resistant.*
FDA Label Image

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 01)

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 01)
This is a description of a medication named Levetiracetam provided by the Major pharmaceutical company. The medication is available in tablet form and comes in a unit dose package. The package contains 100 tablets, each containing 500 mg of Levetiracetam USP. The recommended dosage is not indicated but can be found in the product insert or complete precautions and warnings. The package is not child-resistant and should be stored at temperatures between 20-25°C (68-77°F) with excursions permitted up to 15-30°C (55-86°F) as per USP standards. No other information is available from the text provided.*
FDA Label Image

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 02)

Carton Label (C4b27429 50a3 467c A5ff 7e49a01a1088 02)
This is a description of a medication called Levetiracetam Tablets USP made by Major with NDC number 0904-7123-61 and dispensed in a unit dose. The medication comes in a package with 100 tablets that should be stored at a temperature between 20 and 25°C. The pharmacist is instructed to dispense the medication with a medication guide. The insert/med guide can be found on Variaorpharaceuticals.com. The text also includes a warning to keep the medication and all drugs out of reach of children as the unit dose package is not child-resistant.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This is a figure (Figure 2) showing the responder rate (250% reduction from baseline) in Study 2 for a certain drug. The figure depicts the percentage of patients who responded to the drug at different dosages (levetiracetam 1000mg/day and 2000mg/day) compared to placebo. There is a statistically significant difference noted between the patients taking the drug at 2000mg/day and the placebo group.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
The figure shows the responder rate in Study 3, with a greater than 50% reduction from baseline. The percentage for placebo was 14.4%, while the percentage for Levetiracetam 3000 mg/day was 45%. The difference was statistically significant.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
The figure shows the responder rate in Study 4, with a 50% reduction from baseline. The percentage for the placebo group is 44.6% and for the Levetiracetam group is 45%. The graph indicates a statistically significant difference between the two groups.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The figure shows the Responder Rate for patients aged 1 month to less than 4 years in Study 5, with a reduction of more than 50% from baseline. Lovetracatam (4-58) had a statistically significant result compared to the placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The figure shows the responder rate in PGTC seizure frequency per week in Study 7. The percentage reductions from the baseline are plotted on the y-axis, with 100% at the top and 0% at the bottom. The x-axis shows the treatment groups, with placebo and Levetiracetam. The responder rates were 72.2% for Levetiracetam and 45.2% for placebo. The difference between the two groups was statistically significant. Nine percent of patients in the study exhibited no response.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.